Familial glucocorticoid deficiency (FGD) is characterized clinically by severe glucocorticoid deficiency associated with failure of adrenal responsiveness to ACTH but not with mineralcorticoid deficiency. Excessive growth was described previously in some patients with FGD, many of whom were shown to have mutations in the ACTH receptor gene. The mechanisms responsible for their excessive growth are unknown. We analyzed the ACTH receptor gene in three patients with FGD and discussed the causes of excessive growth in FGD. No mutations were detected in the coding and promoter regions of the ACTH receptor gene of one female patient who had tall stature (+ 2.41S.D.) and advanced bone age (10 years 9 months) when she was 4 years 9 months old. Her plasma ACTH level had been elevated until then (124-2,684 pg/ml). Moreover, plasma estradiol was elevated for her age (21.3 pg/ml), and it decreased in response to the dexamethasone suppression test (from 25.4 to 6.9 pg/ml). Elevated plasma estradiol was apparently related to the increase in plasma ACTH and played a major role in excessive growth in this patient. On the other hand, the genetic analysis showed that the other two patients who were siblings were homozygous for the R137W mutation. Clinically, they responded well to hydrocortisone replacement therapy with almost normal plasma ACTH levels. Although all patients with the R137W mutation reported previously were tall, our patients were of normal height. We speculate that the major causes of excessive growth in FGD are not only from ACTH receptor mutation, but also from the action of elevated plasma ACTH. familial glucocorticoid deficiency; excessive growth; estradiol; ACTH receptor mutation; elevated plasma ACTH
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Familial glucocorticoid deficiency (FGD) is a rare autosomal recessive disorder, and is characterized clinically by severe glucocorticoid deficiency associated with failure of adrenal responsiveness to ACTH but not with mineralcorticoid deficiency. Following cloning of the ACTH receptor gene (Mountjoy et al. 1992) , some cases of FGD have been reported to have mutations in the coding region of the gene (Clark et al. 1993; Tsigos et al. 1993 Tsigos et al. , 1995 Weber et al. 1995; Tohoku J. Exp. Med., 2005, 205, 123-131 drome. Endocrinological analysis revealed extremely low serum cortisol (2.9 μ g/100 ml), elevated plasma ACTH (1,000 pg/ml), and low plasma 17α -hydroxyprogesterone (0.4 ng/ml). Serum electrolytes were within normal ranges (sodium 136 mEq/liter, potassium 4.7 mEq/liter, chloride 107 mEq/liter). A rapid ACTH test (0.25 mg/m 2 bolus i.v., with blood sampling at 0, 30, 60
and 120 minutes) indicated no increase in serum cortisol throughout the test (Table 1) . Consequently, she was diagnosed as having adrenal insufficiency, and hydrocortisone replacement therapy was introduced (20 mg/m 2 /day) at the age of 11 months. When she was 4 years and 9 months old, a furosemide provocation test showed a good response of plasma aldosterone (Table 1) . Plasma dehydroepiandrosterone sulfate (DHEA-S) was within Naville et al. 1996; Wu et al. 1998; Berberoglu et al. 2001) and are classified as FGD type 1. However, many FGD patients do not have mutations in the coding exon of the ACTH receptor gene (Weber and Clark 1994; Naville et al. 1996 Naville et al. , 1998 , and they are classified as FGD type 2.
FGD is frequently associated with tall stature (Kershnar et al. 1972; Coulter et al. 1991; Weber et al. 1995; Clark and Weber 1998; Slavotinek et al. 1998; Elias et al. 2000) . Clark and Weber (1998) noted that several children with FGD were of tall stature and that the majority of them had ACTH receptor mutations, whereas those children with FGD but without such mutations were generally of normal height. However, all patients with the same mutation did not have tall stature (Weber et al. 1995) . The mechanism of excessive growth in FGD is unknown.
We analyzed the ACTH receptor gene in one FGD patient with tall stature and two FGD patients with normal height to explore whether or not the only major cause of excessive growth in FGD is from ACTH receptor mutation. The dibutyryl cyclic AMP stimulation test was performed to detect a post receptor abnormality in adrenocortical cells after cyclic AMP production in the patient without ACTH receptor mutation. In addition, since plasma estradiol was excessive when plasma ACTH was elevated in the patient with tall stature, we performed the dexamethasone suppression test to explore the relationship between plasma estradiol and plasma ACTH. We compared these results to the clinical findings in each case, focusing on the causes of excessive growth in FGD type 1 and type 2.
MATERIALS AND METHODS

Subject
Patient 1. Patient 1 was a female, who was born to non-consanguineous Japanese parents after an uneventful vaginal delivery at 40 weeks of gestation, with a birth weight of 2,960 g. At 8 months of age, she was referred to a medical institution due to generalized hyperpigmentation. Her external genitalia showed normal development for her age without any evidence of virilization such as clitromegaly. Furthermore, there were no signs of achalasia or alacrima which are noted in triple A syn- After 1 mg/kg furosemide was administered in the supine position at rest, the upright position was maintained for 60 min to examine the effect of the renin-angiotensin system on aldosterone secretion.
Normal range: 11.1-334 pg/ml (8 years old, male), < 402 pg/ml (4 years old, female)
Normal response was assumed when the stimulated plasma aldosterone level exceeded the base line level at least 2-fold. a samples taken while on hydrocortisone. normal range (< 50 ng/ml). Thus, a diagnosis of FGD was confirmed. The level of plasma ACTH had been elevated until then (124-2,684 pg/ml). At that time, her height was 114.2 cm (+2.41 S.D.) (father's height: 169 cm, mother's height: 154 cm) and her bone age was 10 years 9 months (TW2 RUS method standardized for Japanese children) (Fig 1A) . Her height velocity was 10.3 cm/year (+4.73 S.D.) (Table 2 ). Breast development was at Tanner stage II, pubic hair development at Tanner stage I, and plasma estradiol was elevated for her age (21.3 pg/ml). The gonadotropin-releasing hormone (GnRH) stimulation test using 100 μ g/m 2 of GnRH administered as bolus i.v. and taking blood samples at 0, 30, 60, 90 and 120 minutes after the injection to evaluate the responses of LH and FSH. Plasma LH levels were suppressed throughout the test and FSH increased significantly for her age (LH basal: < 0.5, peak: < 0.5 mIU/ ml, FSH basal: 0.9, peak: 9.9 mIU/ml). The levels of plasma insulin-like growth factor 1 (170.5 ng/ml), TSH (3.08 μ U/ml), free T3 (3.6 pg/ml), free T4 (1.2 ng/100 ml), and testosterone (< 5 ng/100 ml), and the response of plasma GH to the insulin tolerance test (basal: 4.8, peak 16.0 ng/ml) were all within normal ranges. Magnetic resonance imaging of her brain, and ultrasonography of her ovaries were also normal. The dosage of hydrocortisone replacement therapy was gradually increased to 25 mg/m 2 /day. Consequently, plasma ACTH was reduced (7 -42 pg/ml) and plasma estradiol was normalized (< 5 pg/ml) with a slowing of the acceleration of bone age (Fig. 1A) . Patient 2. A male patient with a birth weight of 3,190 g was born to non-consanguineous Japanese parents after a vaginal delivery with the use of forceps at 42 weeks of gestation. Generalized hyperpigmentation was present since birth. The development of his external genitalia was normal for his age. At 15 days of age, endocrinological analysis showed extremely low serum cortisol (1.8 μ g/100 ml), elevated plasma ACTH (2,100 pg/ml), and low plasma 17α -hydroxyprogesterone level (< 0.1 ng/ml). Serum electrolytes were within normal ranges (sodium 137 mEq/liter, potassium 4.8 mEq/liter, chloride 102 mEq/liter). The rapid ACTH test did not affect serum cortisol (Table 1) . He was diagnosed as having adrenal insufficiency, and hydrocortisone replacement therapy (20 mg/m 2 /day) was introduced when he was 1 month old. When he was 8 years and 10 months old, a furosemide provocation test showed a good response of plasma aldosterone (Table 1) . Plasma DHEA-S (< 50 ng/ml) and plasma testosterone (< 5 ng/100 ml) were within normal ranges. Thus, a diagnosis of FGD was confirmed. Plasma estradiol was not elevated (< 5.0 pg/ml) until the age of 9 years 0 month. His growth and development continued to be normal (father's height: 170 cm, mother's height: 155 cm) (Fig.  1B) and plasma ACTH level was almost normal (data not shown) throughout the period of hydrocortisone replacement therapy. Patient 3. The younger sister of Patient 2 was born by an uneventful vaginal delivery at 40 weeks of gestation, with a birth weight of 3,090 g. Generalized hyperpigmentation was also present since birth. Her external genitalia were normal for her age. At 1 month of age, endocrinological analysis showed extremely low serum cortisol (1.4 μ g/100 ml), elevated plasma ACTH (3,200 pg/ml) and low plasma 17α -hydroxyprogesterone (< 0.1 ng/ml). Serum electrolytes were within normal ranges (sodium 137 mEq/liter, potassium 4.8 mEq/liter, chloride 103 mEq/liter). The rapid ACTH test did not affect serum cortisol (Table 1) . She was diagnosed as having adrenal insufficiency and hydrocortisone replacement ther- apy (20 mg/m 2 /day) was introduced when she was 1 month old. When she was 4 years and 6 months old, the furosemide provocation test showed a good response of plasma aldosterone (Table 1) . Plasma DHEA-S (< 50 ng/ml) and plasma testosterone (< 5 ng/100 ml) were within normal ranges. On the basis of these findings, a diagnosis of FGD was also confirmed. Her growth and development continued to be normal (Fig. 1C ) and plasma ACTH level was almost normal (data not shown) throughout the period of hydrocortisone replacement therapy. Plasma estradiol was not elevated (< 5.0 pg/ml) until the age of 9 years 11 months.
DNA preparation and analysis
Investigations of the ACTH receptor gene were performed with the approval of the institutional review board of the Nagoya City University Graduate School of Medical Sciences Institute for Molecular Research, and informed consent for the investigation was obtained from all patients' parents.
Genomic DNA was extracted from 200 μ l of venous blood using a commercial kit (QIAamp DNA blood mini kit; Qiagen, Tokyo). All polymerase chain reaction (PCR) analyses were carried out on 2-μ l samples of each DNA preparation in a 20 μ l reaction volume containing 0.5 U gold Taq polymerase (Takara, Otsu), 125 μ M of each deoxyribonucleoside triphosphate, 0.5 μ M of each primer pair, 50 mM KCl, 1.5 mM MgCl 2 , and 10 mM Tris HCl (pH 8.3). The entire coding and promoter sequence of the ACTH receptor gene was amplified by PCR, using the primers shown in Table 3 ; sense oligonucleotide 1 and antisense oligonucleotide 2 for the promoter region, sense oligonucleotide 3 and antisense oligonucleotide 4 for the 5'-fragment of the coding region, and oligonucleotide 5 and antisense oligonucleotide 6 for the 3'-fragment of the coding region. PCR for the promoter region was started by an extended denaturation of 5 minutes at 95°C followed by 40 cycles of 30 seconds at 95°C, 30 seconds at 55°C, and 2 minutes at 72°C followed by an extension at 72°C for 7 minutes, and the PCR for the coding region was started by an extended denaturation of 5 minutes at 95°C followed by 30 cycles of 30 seconds at 95°C, 30 seconds at 58°C, and 40 seconds at 72°C followed by an extension at 72°C for 7 minutes in a commercial cycling system (GeneAmp PCR System 9700; Applied Biosystems, Chiba). The amplified DNA products were separated by electrophoresis through a 2% agarose gel, stained with ethidium bromide, and visualized using an ultraviolet trans-illuminator. The amplified products were extracted from the agarose gel and purified using a commercial kit (QIAquick gel extraction kit; Qiagen) and were directly sequenced in both directions by a fluorescent dye terminator cycle system, using the specific primers described above and a commercial DNA sequencing kit (Biosystems) and auto-analyzer (ABI PRISM 310 Genetic Analyzer; Applied Biosystems), according to the manufacturer's instructions.
Dibutyryl cyclic AMP stimulation test
For the patient without ACTH receptor mutations, the dibutyryl cyclic AMP stimulation test was performed to detect a post receptor abnormality in adrenocortical cells after cyclic AMP production. After overnight fasting, dibutyryl cyclic AMP (12 mg/kg) dissolved in 200 ml of physiological saline was infused i.v., at a rate of 0.2 mg/kg/min for 60 minutes to the patient in the supine position. Venous blood samples were taken at 0, 30, 60, 90 and 120 minutes after the infusion to estimate serum cortisol and plasma glucose (Fukuda et al. 1986; Yamaoka et al. 1992 ). Blood pressure and heart rate were monitored during the test.
Dexamethasone suppression test
In patient 1, the dexamethasone suppression test was performed to explore the relationship between plasma estradiol and plasma ACTH using a modification of the method described previously (Liddle 1960; Nugent et al. 1965 ). Dexamethasone at a dose of 0.25 mg was given orally every 6 hours was administered for a total of 8 doses. Venous blood samples were taken before dexa- The oligonucleotides are numbered from 5' to 3', and were either sense or antisense.
Nucleotide numbers of primers 1 and 2 were calculated from the major transcription start site.
Nucleotide numbers of primers 3, 4, 5 and 6 were calculated from the ATG codon. methasone administration on the morning of the first day of the test and on the second, third and fourth mornings during the test. Serum cortisol, plasma estradiol and ACTH were assayed.
RESULTS
Molecular analysis
In patient 1 who had tall stature and advanced bone age, no mutations in the coding region of the ACTH receptor gene were detected. In addition, no mutations in the promoter region of ACTH receptor gene were found. In both patients 2 and 3, who were of normal height, we detected a homozygous mutation in the coding region of the ACTH receptor gene, a cytosine to thymidine transition at the first position of codon 137, resulting in substitution of arginine for tryptophan (R137W) (Fig. 2A, B) . The mutation is in the second intracellular loop of the receptor and may impair G protein coupling (Flück et al. 2002) .
Dibutyryl cyclic AMP stimulation test
Patient 1, who had no mutations in the ACTH receptor gene, showed little change in serum cortisol from 4.3 to 2.6 μ g/100 ml from the dibutyryl cyclic AMP stimulation test. However, her plasma glucose concentration increased from 102 to 198 mg/100 ml, similarly to the response of a normal subject (Fukuda et al. 1986; Yamaoka et al. 1992) . During the infusion, diastolic blood pressure decreased from 64 to 44 mmHg and heart rate did not increase (Table 4) . Plasma glucose and cortisol are distinctly increased in normal adults, but the normal range in children is not clear.
Dexamethasone suppression test
In patient 1, plasma ACTH decreased from 65 to less than 3 pg/ml and serum cortisol decreased from 3.9 to below 1.0 μ g/100 ml in response to dexamethasone. Similarly, plasma estradiol decreased from 25.4 to 6.9 pg/ml (Table 5 ).
DISCUSSION
The majority of patients diagnosed as FGD type 1 are of tall stature, whereas patients diagnosed as FGD type 2 are generally of normal height . However, the mechanism responsible for excessive growth in FGD is unknown. We analyzed the ACTH receptor gene in three FGD patients. Patient 1 has no mutations in the coding and promoter regions of the ACTH receptor gene. After dibutyryl cyclic AMP infusion, serum cortisol did not increase, despite an increase in plasma glucose similar to that in a normal subject (Yamaoka et al. 1992) . We considered that patient 1 has FGD type 2, and that the defect could be due to a post receptor abnormality occurring in adrenocortical cells after cyclic AMP production (Fukuda et al. 1986; Yamaoka et al. 1992 ). However, she had tall stature and advanced bone age. On the other hand, in our patients 2 and 3, genetic analysis showed a homozygous R137W mutation in the ACTH receptor gene. We considered that patients 2 and 3 have FGD type 1. The R137W mutation was reported in three previous cases (Katsumata et al. 1998; Ishii et al. 2000; Flück et al. 2002) , all of whom were tall. However, our patients were of normal height. These results are contrary to the relationship between ACTH receptor mutation and tall stature previously described . Thus, we surmised that FGD has another major cause of excessive growth other than the effects of ACTH receptor mutation.
In the present study, in patient 1 who has no mutations in the ACTH receptor gene, plasma ACTH and estradiol were elevated when her growth velocity was accelerated. Her plasma insulin-like growth factor 1, TSH, free T3, free T4, and testosterone levels, and the response of plasma GH to the insulin tolerance test, were all within normal ranges. Plasma estradiol decreased in response to the dexamethasone suppression test. Moreover, after plasma ACTH was reduced and plasma estradiol was normalized in response to increased hydrocortisone replacement therapy, the rates of her bone ageing and growth velocity were also reduced. Thus, elevated plasma estradiol was apparently related to the increase in plasma ACTH in this patient. This is the first report of elevated plasma estradiol in FGD with tall stature. Elevated plasma ACTH may have indirectly affected the increase in height and advanced bone age due to an increase in plasma estradiol in patient 1. In patients 2 and 3 who are homozygous for the R137W mutation, hydrocortisone replacement therapy was introduced at the age of 1 month and their plasma ACTH levels remained almost normal after clinical intervention, and they were of normal height. On the other hand, three patients with the R137W mutation described previously had tall stature. In two of three patients (Katsumata et al. 1998; Flück et al. 2002) , hydrocortisone replacement therapy was introduced after the age of 2 years, but they already had tall stature for their age before clinical intervention. In the third patient (Ishii et al. 2000) , hydrocortisone replacement therapy was introduced at 3 months of age. However, this patient's compli- Plasma ACTH (pg/ml) 65 < 3 < 3 5 Serum cortisol (μ g/100 ml) 3.9 1.5 < 1.0 16.4 Plasma estradiol (pg/ml) 25.4 9.3 6.9 11.6
Plasma ACTH was decreased to less than 10 pg/ml in normal subjects after the dexamethasone suppression test.
ance with the therapy was poor and plasma ACTH levels remained high, and later this patient also became tall. Thus, elevated plasma ACTH level may have as yet unrecognized actions on growth as previously suggested (Elias et al. 2000) . From a previous report , we considered that ACTH receptor mutation is related to excessive growth in FGD type 1. However, there may be another important cause of excessive growth in FGD. We suggest that the action of elevated plasma ACTH is possibly a major cause of excessive growth in both of FGD type 1 and type 2 in the presence or absence of ACTH receptor mutation.
In summary, we compared the results of molecular analyses of the ACTH receptor gene with the clinical findings in three patients with FGD. Patient 1 who had no mutations in the ACTH receptor gene was of tall stature. It appears that elevated plasma estradiol level was related to the increase in plasma ACTH and played a major role in excessive growth and advanced bone age in this patient. On the other hand, patients 2 and 3 who were homozygous for the R137W mutation were of normal height and their plasma ACTH levels remained almost normal, in contrast to patients with the R137W mutation described previously. From these results, we speculate that the major causes of excessive growth in FGD are not only from ACTH receptor mutation, but also from the action of elevated plasma ACTH.
